Cost utility analysis (CUA) of nivolumab compared to everolimus for the treatment of metastatic renal cell carcinoma (RCC) in Australia

Liew, D., Patten, N., Tan, M. and Kim, H. 2017, Cost utility analysis (CUA) of nivolumab compared to everolimus for the treatment of metastatic renal cell carcinoma (RCC) in Australia, Value in health, vol. 20, no. 9, October-November, pp. A444-A444, doi: 10.1016/j.jval.2017.08.260.

Attached Files
Name Description MIMEType Size Downloads

Title Cost utility analysis (CUA) of nivolumab compared to everolimus for the treatment of metastatic renal cell carcinoma (RCC) in Australia
Author(s) Liew, D.
Patten, N.
Tan, M.
Kim, H.
Journal name Value in health
Volume number 20
Issue number 9
Season October-November
Start page A444
End page A444
Total pages 1
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2017-10
ISSN 1098-3015
Language eng
DOI 10.1016/j.jval.2017.08.260
Field of Research 1117 Public Health And Health Services
1402 Applied Economics
HERDC Research category C2 Other contribution to refereed journal
Copyright notice ©2017, Elsevier
Persistent URL http://hdl.handle.net/10536/DRO/DU:30113664

Document type: Journal Article
Collection: Population Health
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 3 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 12 Sep 2018, 11:51:38 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.